gefällt mir auch gut BELLUS Health Inc
(TSE:BLU)
https://www.google.com/finance…BLU&ei=nq4XUqCbK8qVwQPyRA
haben eben Thallion Pharmaceuticals Inc.
(TSE:TLN) https://www.google.com/finance…LN&ei=2rMXUoiPCIWDwAOeggE eingeheimst..
16% der untigen pipline gehören nun auch Bellus
http://www.caprion.com/en/in-vitro-diagnostics/pipeline.php
[Blockierte Grafik: http://www.caprion.com/medias/img/DXpipeline_000.jpg]
Bellus eigene pipline:
Products
The Company’s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
BELLUS Health’s primary focus is on advancing KIACTA™, a novel first-in-class treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study that is currently enrolling patients.
The Company is also developing BLU8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease. BLU8499 is expected to begin a Phase IIa proof of concept study in the second half of 2014.
VIVIMIND™ is a commercial-stage, cash-flow positive nutraceutical product for memory protection. BELLUS Health has established distribution partnerships for VIVIMIND™ in several countries, including Italy, Canada, Taiwan, Greece, certain countries in the Middle East, Israel and South Korea.
[Blockierte Grafik: http://www.bellushealth.com/files/pipe_en_1.jpg]
dazu würde noch die pipeline von Thallion kommen:
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its product candidates include: Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections and TLN-4601, a proprietary first-in-class small molecule with potential efficacy in multiple oncology indications. The Company also owns technology platform named DECIPHER, a genomics-based discovery platform technology. Its Shigamabs product consists of two monoclonal antibodies designed to bind specifically to Shiga toxin 1 and Shiga toxin 2 secreted by STEC. It has completed four Phase I clinical trials evaluating the safety of Shigamabs.
das ganze fürne marktkap. von 19 mio !!